U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H16NO2
Molecular Weight 146.2074
Optical Activity NONE
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of ACETYLCHOLINE

SMILES

CC(=O)OCC[N+](C)(C)C

InChI

InChIKey=OIPILFWXSMYKGL-UHFFFAOYSA-N
InChI=1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1

HIDE SMILES / InChI

Molecular Formula C7H16NO2
Molecular Weight 146.2074
Charge 1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity NONE

Acetylcholine is the neurotransmitter at neuromuscular junctions, at synapses in the ganglia of the visceral motor system, and at a variety of sites within the central nervous system. Whereas a great deal is known about the function of cholinergic transmission at the neuromuscular junction and at ganglionic synapses, the actions of acetylcholine in the central nervous system are not as well understood. Cholinergic system is an important system and a branch of the autonomic nervous system which plays an important role in memory, digestion, control of heart beat, blood pressure, movement and many other functions. Acetylcholine in the brain alters neuronal excitability, influences synaptic transmission, induces synaptic plasticity, and coordinates firing of groups of neurons. Miochol®-E (acetylcholine chloride intraocular solution) is used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
MIOCHOL-E

Approved Use

To obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required

Launch Date

1993
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

PubMed

PubMed

TitleDatePubMed
Functional reconstitution and characterization of recombinant human alpha 1-glycine receptors.
2001-06-15
Gyroxin fails to modify in vitro release of labelled dopamine and acetylcholine from rat and mouse striatal tissue.
2001-06
Conversion of the ion selectivity of the 5-HT(3a) receptor from cationic to anionic reveals a conserved feature of the ligand-gated ion channel superfamily.
2001-04-06
Identification of a basolateral sorting signal for the M3 muscarinic acetylcholine receptor in Madin-Darby canine kidney cells.
2001-03-30
Anti-neuronal nicotinic receptor antibodies in MG patients with thymoma.
2001-02-01
Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis.
2001-02-01
Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR.
2001-02-01
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
2001-01-12
Post-ictal analgesia: involvement of opioid, serotoninergic and cholinergic mechanisms.
2001-01-12
Changes in sensitivity of cholinoceptors and adrenoceptors during transhemispheric cortical reorganisation in rat SmI.
2001-01-12
Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome.
2001-01-09
Site of resting state inhibition of the nicotinic acetylcholine receptor by a hydrophobic inhibitor.
2001-01-09
Antagonist of nicotinic acetylcholine receptors (nAChR) enhances formalin-induced nociception in rats: tonic role of nAChRs in the control of pain following injury.
2001-01-05
Aversive hypothalamic stimulation releases acetylcholine in the nucleus accumbens, and stimulation-escape decreases it.
2001-01-05
exo-2-(Pyridazin-4-yl)-7-azabicyclo[2.2.1]heptanes: syntheses and nicotinic acetylcholine receptor agonist activity of potent pyridazine analogues of (+/-)-epibatidine.
2001-01-04
Exercise training in coronary artery disease and coronary vasomotion.
2001-01-02
Role of calcium-sensitive K(+) channels and nitric oxide in in vivo coronary vasodilation from enhanced perfusion pulsatility.
2001-01-02
beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice.
2001-01-01
A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans.
2001-01-01
Bi-directional activation between human airway smooth muscle cells and T lymphocytes: role in induction of altered airway responsiveness.
2001-01-01
Allergen-specific Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN-gamma.
2001-01-01
Projections and pathways of VIP- and nNOS-containing airway neurons in ferret trachea.
2001-01
Arterial remodeling in chronic sinoaortic-denervated rats.
2001-01
Effects of LY117018 and the estrogen analogue, 17alpha-ethinylestradiol, on vascular reactivity, platelet aggregation, and lipid metabolism in the insulin-resistant JCR:LA-cp male rat: role of nitric oxide.
2001-01
Rapid eye movement sleep deprivation induces an increase in acetylcholinesterase activity in discrete rat brain regions.
2001-01
Coronary endothelial dysfunction after ischemia and reperfusion: a new therapeutic target?
2001-01
Dynamic restoration of dystrophin to dystrophin-deficient myotubes.
2001-01
Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats.
2001-01
Association study of a nicotinic receptor variant with schizophrenic disorders.
2001-01
Platelet-derived growth factor is involved in the augmentation of airway responsiveness through remodeling of airways in diesel exhaust particulate-treated mice.
2001-01
An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope.
2001-01
Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C.
2001-01
Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum.
2001-01
Mechanical efficiency of isolated in situ perfused hearts of the eel Anguilla australis.
2001-01
Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia.
2001-01
Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
2001-01
Exercise and the endothelium.
2001-01
Ischemic preconditioning with opening of mitochondrial adenosine triphosphate-sensitive potassium channels or Na/H exchange inhibition: which is the best protective strategy for heart transplants?
2001-01
Cortical acetylcholine release elicited by stimulation of histamine H1 receptors in the nucleus basalis magnocellularis: a dual-probe microdialysis study in the freely moving rat.
2001-01
Extracellular cyclic ADP-ribose potentiates ACh-induced contraction in bovine tracheal smooth muscle.
2001-01
Specification of neurotransmitter receptor identity in developing retina: the chick ATH5 promoter integrates the positive and negative effects of several bHLH proteins.
2001-01
Environmental familiarization in rats: differential effects of acute and chronic nicotine.
2001-01
Influence of gender and sex hormones on nicotine acute pharmacological effects in mice.
2001-01
A new hypoglycemic agent, JTT-608, evokes protein kinase A-mediated Ca(2+) signaling in rat islet beta-cells: strict regulation by glucose, link to insulin release, and cooperation with glucagon-like peptide-1(7-36)amide and pituitary adenylate cyclase-activating polypeptide.
2001-01
Adrenal tyrosine hydroxylase activity and gene expression are increased by intraventricular administration of nicotine.
2001-01
Myocardial stunning in exercise-induced ischemia in dogs: lack of late preconditioning.
2001-01
Glutathione attenuates coronary constriction to acetylcholine in patients with coronary spastic angina.
2001-01
Vagosympathetic interactions in ischemia-induced myocardial norepinephrine and acetylcholine release.
2001-01
Electrical activation of endothelium evokes vasodilation and hyperpolarization along hamster feed arteries.
2001-01
Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
2000-12-23
Patents

Sample Use Guides

Miochol®-E (acetylcholine chloride intraocular solution) is instilled into the anterior chamber before or after securing one or more sutures. Instillation should be gentle and parallel to the iris face and tangential to pupil border. If there are no mechanical hindrances, the pupil starts to constrict in seconds and the peripheral iris is drawn away from the angle of the anterior chamber. Any anatomical hindrance to miosis must be released to permit the desired effect of the drug. In most cases, 0.5 to 2 mL produces satisfactory miosis. Note that the syringe filter supplied with Miochol-E has a priming volume of 0.6 mL (approximately). In cataract surgery, use Miochol-E only after delivery of the lens. Aqueous solutions of acetylcholine chloride are unstable. Prepare solution immediately before use. Do not use solution which is not clear and colorless. Discard any solution that has not been used.
Route of Administration: Other
Keratocytes were treated with various concentrations of acetylcholine (0.01-1 uM) for 24 h. Acetylcholine enhances keratocyte proliferation through activation of muscarinic acetylcholine receptors.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:04:25 GMT 2025
Edited
by admin
on Mon Mar 31 18:04:25 GMT 2025
Record UNII
N9YNS0M02X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACETYLCHOLINE CATION
Preferred Name English
ACETYLCHOLINE
VANDF   WHO-DD  
Systematic Name English
Acetylcholine [WHO-DD]
Common Name English
CHOLINE ACETATE (ESTER)
Common Name English
ACETYLCHOLINE [VANDF]
Common Name English
ACETYLCHOLINE [USP IMPURITY]
Common Name English
ETHANAMINIUM, 2-(ACETYLOXY)-N,N,N-TRIMETHYL-
Systematic Name English
Classification Tree Code System Code
LOINC 1707-9
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
DSLD 3695 (Number of products:2)
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
WHO-ATC S01EB09
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
NCI_THESAURUS C47796
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
NDF-RT N0000175884
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
NDF-RT N0000175369
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
WHO-VATC QS01EB09
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
Code System Code Type Description
DRUG CENTRAL
65
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
EVMPD
SUB00261MIG
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
LACTMED
Acetylcholine
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
PUBCHEM
187
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
DRUG BANK
DB03128
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
MESH
D000109
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
NCI_THESAURUS
C77840
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
DAILYMED
N9YNS0M02X
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
SMS_ID
100000078828
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
CHEBI
15355
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
WIKIPEDIA
ACETYLCHOLINE
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
RXCUI
194
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY RxNorm
ECHA (EC/EINECS)
200-128-9
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
FDA UNII
N9YNS0M02X
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
EPA CompTox
DTXSID8075334
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
CAS
51-84-3
Created by admin on Mon Mar 31 18:04:25 GMT 2025 , Edited by admin on Mon Mar 31 18:04:25 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
ACETYLCHOLINE (ACH) IS AN ORGANIC CHEMICAL THAT FUNCTIONS IN THE BRAIN AND BODY OF MANY TYPES OF ANIMALS, INCLUDING HUMANS, AS A NEUROTRANSMITTERA CHEMICAL MESSAGE RELEASED BY NERVE CELLS TO SEND SIGNALS TO OTHER CELLS (NEURONS, MUSCLE CELLS, AND GLAND CELLS).
SALT/SOLVATE -> PARENT
INHIBITOR OF EFFLUX->TARGET
Inhibits exocytosis of acetylcholine at nerve endings
Related Record Type Details
PARENT -> IMPURITY
USP
Related Record Type Details
ACTIVE MOIETY